Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIVE-N: Vepdegestrant vs Anastrozole in Neoadjuvant ER+/HER2- Breast Cancer
NCT05549505Phase 2Completed
- Sponsor
- Arvinas
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of vepdegestrant in breast cancer (2 arms), sponsored by Arvinas. Primary endpoint: Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies. Started Feb 2023; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05549505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549505.